Literature DB >> 15057783

Immunotherapeutic uses of CpG oligodeoxynucleotides.

Dennis M Klinman1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15057783     DOI： 10.1038/nri1329

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN： 1474-1733            Impact factor:   53.106


× No keyword cloud information.
  247 in total

1.  Transdermal immunization using solid-in-oil nanodispersion with CpG oligodeoxynucleotide adjuvants.

Authors:  Momoko Kitaoka; Ayaka Naritomi; Yuya Hirakawa; Noriho Kamiya; Masahiro Goto
Journal:  Pharm Res       Date:  2014-11-01       Impact factor: 4.200

2.  Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity.

Authors:  Chasity D Andrews; Myung-Sook Huh; Kathryn Patton; Debbie Higgins; Gary Van Nest; Gary Ott; Kyung-Dall Lee
Journal:  Mol Pharm       Date:  2012-04-06       Impact factor: 4.939

3.  Activation of type I interferon-dependent genes characterizes the "core response" induced by CpG DNA.

Authors:  Folkert Steinhagen; Corinna Meyer; Debra Tross; Mayda Gursel; Takahiro Maeda; Sven Klaschik; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2012-07-02       Impact factor: 4.962

4.  Immunostimulatory and anti-neoplasm effects of a novel palindrome CpG oligodeoxynucleotide in mice.

Authors:  Hai-yan Du; Li-hou Dong; Bi-jun Zhao; Jie Fu; Qing-qing Wang; Fang Chen; Lun Ou; Na Li; Xiao Sun; Zhong-ming Tang; Hai-feng Song
Journal:  Acta Pharmacol Sin       Date:  2012-06-25       Impact factor: 6.150

5.  Inflammatory cytokines presented from polymer matrices differentially generate and activate DCs in situ.

Authors:  Omar A Ali; Prakriti Tayalia; Dmitry Shvartsman; Sarah Lewin; David J Mooney
Journal:  Adv Funct Mater       Date:  2013-08-01       Impact factor: 18.808

Review 6.  Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.

Authors:  Jacob J Elmer; Matthew D Christensen; Kaushal Rege
Journal:  J Control Release       Date:  2013-08-30       Impact factor: 9.776

7.  Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.

Authors:  Mariela A Moreno Ayala; María Florencia Gottardo; María Soledad Gori; Alejandro Javier Nicola Candia; Carla Caruso; Andrea De Laurentiis; Mercedes Imsen; Slobodanka Klein; Elisa Bal de Kier Joffé; Gabriela Salamone; Maria G Castro; Adriana Seilicovich; Marianela Candolfi
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-21       Impact factor: 4.553

8.  Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats.

Authors:  Cameron G McCarthy; Camilla F Wenceslau; Styliani Goulopoulou; Safia Ogbi; Babak Baban; Jennifer C Sullivan; Takayuki Matsumoto; R Clinton Webb
Journal:  Cardiovasc Res       Date:  2015-04-24       Impact factor: 10.787

Review 9.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

10.  Intranasal CpG therapy attenuated experimental fungal asthma in a TLR9-dependent and -independent manner.

Authors:  Hemanth Ramaprakash; Cory M Hogaboam
Journal:  Int Arch Allergy Immunol       Date:  2009-12-16       Impact factor: 2.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.